Table 1.
Characteristics of included recipients depending on BMI group
| Characteristics | Obese (n = 609) | Pre-obese (n = 1900) | Normal weight (n = 2904) | Underweight (n = 194) | P-value |
|---|---|---|---|---|---|
| BMI (mean ± SD) | 33.2 ± 3.3 | 27.1 ± 1.4 | 22.3 ± 1.7 | 17.3 ± 1.0 | |
| Recipient variables | |||||
| Primary renal disease | |||||
| Glomerular | 144 (23.6) | 494 (26.0) | 847 (29.2) | 62 (32) | <0.001 |
| Polycystic | 76 (12.5) | 306 (16.1) | 476 (16.4) | 19 (9.8) | – |
| Interstitial | 77 (12.6) | 239 (12.6) | 434 (14.9) | 29 (14.9) | – |
| Vascular | 92 (15.1) | 239 (12.6) | 294 (10.1) | 17 (8.8) | – |
| Diabetes | 84 (13.8) | 143 (7.5) | 139 (4.8) | 7 (3.6) | – |
| Others | 25 (4.1) | 133 (7.0) | 251 (8.6) | 29 (14.9) | – |
| Unknown | 111 (18.2) | 346 (18.2) | 463 (15.9) | 31 (16.0) | – |
| Sex | |||||
| Male | 333 (54.7) | 1274 (67.1) | 1851 (63.7) | 65 (33.5) | <0.001 |
| Age (years) | |||||
| <45 | 130 (21.3) | 397 (20.9) | 1123 (38.7) | 121 (62.4) | <0.001 |
| 45–54 | 160 (26.3) | 501 (26.4) | 679 (23.4) | 30 (15.5) | – |
| 55–64 | 196 (32.2) | 593 (31.2) | 700 (24.1) | 32 (16.5) | – |
| ≥65 | 123 (20.2) | 409 (21.6) | 402 (13.8) | 11 (5.7) | – |
| Morbidity | |||||
| Any cardiovascular morbiditya | 144 (27.7) | 353 (22.5) | 392 (16.8) | 23 (15.2) | <0.001 |
| Diabetes mellitus | 221 (36.7) | 408 (21.7) | 399 (13.8) | 18 (9.3) | <0.001 |
| Hypertension | 352 (79.1) | 865 (71.7) | 115 (63.0) | 64 (56.1) | <0.001 |
| Maximum CDC (%) | |||||
| 0–10 | 503 (83.4) | 1612 (85.1) | 2399 (83.1) | 157 (81.3) | 0.307 |
| 11–50 | 74 (12.3) | 221 (11.7) | 364 (12.6) | 30 (15.5) | – |
| >50 | 26 (4.3) | 61 (3.2) | 124 (4.3) | 6 (3.1) | – |
| Dialysis time before KT (years) | |||||
| ≤1 | 156 (25.6) | 431 (22.7) | 718 (24.7) | 47 (24.2) | 0.610 |
| 1–2 | 150 (24.6) | 511 (26.9) | 727 (25.0) | 50 (25.8) | – |
| >2 | 303 (49.8) | 958 (50.4) | 1459 (50.2) | 97 (50.0) | – |
| Donor variables | |||||
| Donor type | |||||
| Deceased | 541 (88.8) | 1756 (92.4) | 2630 (90.6) | 173 (89.2) | 0.022 |
| Living donor | 68 (11.2) | 144 (7.6) | 274 (9.4) | 21 (10.8) | |
| Sex | |||||
| Male | 351 (57.9) | 1123 (59.5) | 1734 (60.1) | 116 (59.8) | 0.790 |
| Age (years) | |||||
| <45 | 173 (28.5) | 576 (30.5) | 1152 (40.0) | 104 (54.2) | <0.001 |
| 45–54 | 147 (24.2) | 394 (20.9) | 651 (22.6) | 39 (20.3) | – |
| 55–64 | 156 (25.7) | 492 (26.1) | 615 (21.3) | 28 (14.6) | – |
| ≥65 | 131 (21.6) | 425 (22.5) | 465 (16.1) | 21 (10.9) | – |
| Hepatitis C virus positive | 8 (1.6) | 23 (1.5) | 46 (2.0) | 6 (3.9) | 0.160 |
| Transplant procedure | |||||
| Period | |||||
| 1990–2000 | 167 (27.4) | 719 (37.8) | 1245 (42.9) | 83 (42.8) | <0.001 |
| 2001–11 | 442 (72.6) | 1181 (62.2) | 1659 (57.1) | 111 (57.2) | – |
| Cold ischaemia time (h) | |||||
| 0–18 | 328 (59.7) | 959 (57.7) | 1526 (60.5) | 101 (62.0) | 0.392 |
| 19–24 | 171 (31.1 | 529 (31.8) | 739 (29.3) | 42 (25.8) | – |
| >24 | 50 (9.1) | 174 (10.5) | 257 (10.2) | 20 (12.3) | – |
| Immunosuppression treatment during the first 6 weeks | |||||
| Tacrolimus | 314 (51.5) | 876 (48.9) | 1336 (48.3) | 94 (50.5) | 0.051 |
| Cyclosporine | 177 (30.8) | 682 (38.1) | 1122 (40.7) | 79 (42.5) | <0.001 |
| Mycophenolate | 449 (78.1) | 1257 (70.1) | 1857 (67.2) | 117 (62.9) | <0.001 |
| Basiliximab/daclizumab | 218 (38.2) | 549 (30.8) | 687 (25.1) | 41 (22.3) | <0.001 |
| Number of matches between donor and recipient (HLA-A, HLA-B and HLA-DR) | |||||
| 0 | 44 (7.3) | 118 (6.2) | 147 (5.1) | 14 (7.3) | 0.098 |
| 1 | 135 (22.4) | 385 (20.3) | 653 (22.6) | 34 (17.6) | – |
| 2 | 210 (34.9) | 689 (36.4) | 985 (34.1) | 67 (34.7) | – |
| 3 | 160 (26.6) | 508 (26.8) | 847 (29.3) | 60 (31.1) | – |
| ≥4 | 53 (8.8) | 194 (10.2) | 255 (8.8) | 18 (9.3) | – |
Values presented as n (%).
a
Ischaemic heart disease, cardiomyopathy, cardiac conduction disorders, cerebrovascular disease or vascular disease. CDC, classic complement-dependent cytotoxicity crossmatch technique.